A Phase 1 interventional study of HJB647 and Placebo in Elevated Blood Pressure and Hypertension, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in Japan. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies in Hypertension by Novartis — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · Novartis.
Among the 227 studies in Hypertension by Novartis, this one is the 180th largest by planned enrollment of the 222 interventional ones that give a count, is one of 4 that started in 2026, is one of 17 in phase 1, and was the 227th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →4 of the 227 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United Arab Emirates
Ages 18–99
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
Novartis Pharmaceuticals · Sites in United States, Japan, Singapore
Ages 18+
By country, each count listing its studies:
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 31 · Phase 3 109 · Phase 4 67
First in 1989; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 309 across the 222 interventional studies, 813 across the 4 observational. Of the 219 that completed or were terminated, 88 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
3 of the studies in Hypertension by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07644364Novartis PharmaceuticalsHJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension | 2026-12-25 |
| NCT07610278Novartis PharmaceuticalsA Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia | 2027-04-28 |
| NCT07465666Novartis PharmaceuticalsA Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 227 studies in Hypertension by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacokinetics, and pharmacodynamics of HJB647 following single dose administration in Japanese healthy participants with elevated blood pressure and multiple dose administration with up titration in Japanese patients with hypertension, to support future clinical development of HJB647
Randomized, placebo-controlled, participant- and investigator-blind study consisting of two parts:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Body weight:
Blood pressure criteria are as follows:
Exclusion Criteria:
History or current diagnosis of or cardiac abnormalities indicating significant risk of safety for participants such as:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose Day 1 in Part 1
Drug: HJB647
Single dose Day 1 in Part 1
Drug: HJB647
Single dose Day 1 in Part 1
Drug: HJB647
Single dose Day 1 in Part 1
Drug: Placebo
Multiple oral doses of HJB647 with adaptive up-titration in Part 2
Drug: HJB647
Multiple oral doses of HJB647 with adaptive up-titration in Part 2
Drug: HJB647
Multiple oral doses of HJB647 with adaptive up-titration in Part 2
Drug: HJB647
Multiple oral doses of HJB647 with adaptive up-titration in Part 2
Drug: HJB647
Multiple oral doses of HJB647 with adaptive up-titration in Part 2
Drug: HJB647
Multiple oral doses of placebo with adaptive up-titration in Part 2
Drug: Placebo
HJB647 oral capsule
Matching oral placebo
Part 1: Cmax
Cmax: The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1)
Time frame: Part 1 on Day 1
Part 1: Tmax
Tmax: The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time)
Time frame: Part 1 on Day 1
Part 1: AUClast
AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1)
Time frame: Part 1 on Day 1
Part 1: AUCinf
AUCinf: The AUC from time zero to infinity (mass x time x volume-1)
Time frame: Part 1 on Day 1
Part 1: T1/2
T1/2: The elimination half-life associated with the terminal slope (λz) of a semi logarithmic concentration-time curve (time). Use qualifier for other half-lives
Time frame: Part 1 on Day 1
Part 2: Number of participants with AEs
Number of participants with adverse events (AEs) including abnormal vital signs, ECG, and safety laboratory parameters
Time frame: Up to 51 days
Part 1: Number of participants with AEs
Number of participants with adverse events (AEs) including abnormal vital signs, ECG, and safety laboratory parameters
Time frame: Up to 31 days
Part 2: Cmax
Cmax: The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1)
Time frame: Part 2 Day 1, Day 7, Day 8, Day 14, Day 15 and Day 21
Part 2: Tmax
Tmax: The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time)
Time frame: Part 2 Day 1, Day 7, Day 8, Day 14, Day 15 and Day 21
Part 2: AUClast
AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1)
Time frame: Part 2 Day 1, Day 7, Day 8, Day 14, Day 15 and Day 21
Part 2: AUCinf
AUCinf: The AUC from time zero to infinity (mass x time x volume-1)
Time frame: Part 2 Day 1, Day 7, Day 8, Day 14, Day 15 and Day 21
Part 2: AUCtau
AUCtau: The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1)
Time frame: Part 2 Day 1, Day 7, Day 8, Day 14, Day 15 and Day 21
Part 2: T1/2
T1/2: The elimination half-life associated with the terminal slope (λz) of a semi logarithmic concentration-time curve (time). Use qualifier for other half-lives
Time frame: Part 2 Day 1, Day 7, Day 8, Day 14, Day 15 and Day 21
Part 2: Office blood pressure change from baseline
Change in office blood pressure from baseline
Time frame: Baseline to Day 27 of part 2
Part 2: Heart rate change from baseline
Change in heart rate from baseline
Time frame: Baseline to Day 27 of part 2
Plan to share: No — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.
Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 5 months is above that.
Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.